= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Rappold

MSACL 2018 EU Abstract

Topic: Practical Training

Podium Presentation in the Ether on Thursday at 14:30 (Chair: Brian Rappold)

1/3 Getting Lower Limits of Quantification in LC-MS/MS assays : Prologue

Brian Rappold (Presenter)

Presenter Bio(s): Brian Rappold is the Director of Mass Spectrometry for LabCorp. He's participated in MSACL EU since its inception, leading workshops and teaching short courses related to method development and validation strategies.

Authors: Brian Rappold
Laboratory Corporation of America


Understanding mechanisms to achieving better sensitivity in LC-MS/MS assays must start with fundamentals and first principles of the technology. An initial conversation of noise, response functions, ionization techniques and hardware will introduce attendees to the basics of mechanisms used to reduced needed sample volume, increase instrument response and improve assay precision.

Financial Disclosure

Board MemberyesMetabolomic Diagnostics
Stockyes LabCorp
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: